UA99601C2 - Применение антитела к cd151 для лечения первичных опухолей - Google Patents

Применение антитела к cd151 для лечения первичных опухолей

Info

Publication number
UA99601C2
UA99601C2 UAA200904808A UAA200904808A UA99601C2 UA 99601 C2 UA99601 C2 UA 99601C2 UA A200904808 A UAA200904808 A UA A200904808A UA A200904808 A UAA200904808 A UA A200904808A UA 99601 C2 UA99601 C2 UA 99601C2
Authority
UA
Ukraine
Prior art keywords
cancer
treatment
antibody
medicament
protein
Prior art date
Application number
UAA200904808A
Other languages
English (en)
Ukrainian (uk)
Inventor
Жан-Франсуа Аюв
Лилиан Гетш
Original Assignee
Пьер Фабр Медикаман
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37866318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA99601(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Пьер Фабр Медикаман filed Critical Пьер Фабр Медикаман
Publication of UA99601C2 publication Critical patent/UA99601C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к применению антитела, способного связываться с белком CD151 и ингибировать рост опухолевых клеток, для получения лекарственного средства, предназначенного для лечения первичных опухолей.
UAA200904808A 2006-10-18 2007-10-15 Применение антитела к cd151 для лечения первичных опухолей UA99601C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0609135A FR2907341B1 (fr) 2006-10-18 2006-10-18 Utilisation d'un anticorps anti-cd151 pour le traitement du cancer

Publications (1)

Publication Number Publication Date
UA99601C2 true UA99601C2 (ru) 2012-09-10

Family

ID=37866318

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200904808A UA99601C2 (ru) 2006-10-18 2007-10-15 Применение антитела к cd151 для лечения первичных опухолей

Country Status (28)

Country Link
US (2) US8178096B2 (ru)
EP (1) EP2079482B1 (ru)
JP (2) JP5757646B2 (ru)
KR (1) KR101521863B1 (ru)
CN (1) CN101528256B (ru)
AT (1) ATE499387T1 (ru)
AU (1) AU2007310763B2 (ru)
BR (1) BRPI0717455A2 (ru)
CA (1) CA2665912C (ru)
DE (1) DE602007012743D1 (ru)
DK (1) DK2079482T3 (ru)
ES (1) ES2361696T3 (ru)
FR (1) FR2907341B1 (ru)
HK (1) HK1132904A1 (ru)
HR (1) HRP20110374T1 (ru)
IL (1) IL198043A (ru)
MA (1) MA30777B1 (ru)
MX (1) MX2009003039A (ru)
NO (1) NO20091919L (ru)
NZ (1) NZ575781A (ru)
PL (1) PL2079482T3 (ru)
PT (1) PT2079482E (ru)
RS (1) RS51729B (ru)
RU (1) RU2464041C2 (ru)
SI (1) SI2079482T1 (ru)
TN (1) TN2009000144A1 (ru)
UA (1) UA99601C2 (ru)
WO (1) WO2008049990A2 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
FR2929946B1 (fr) * 2008-04-11 2010-05-28 Pf Medicament Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer
EP2308897A1 (en) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
CN102605057A (zh) * 2012-02-28 2012-07-25 芮屈生物技术（上海）有限公司 癌症病变前期CD151的mRNA水平原位杂交检测试剂盒及检测方法和应用
WO2016081455A1 (en) * 2014-11-17 2016-05-26 Pelican Therapeutics, Inc. Human tnfrsf25 antibody
DK3468998T3 (en) 2016-06-09 2022-03-07 Pelican Therapeutics Inc Anti-tnfrsf25-antistoffer
WO2018184558A1 (zh) * 2017-04-05 2018-10-11 凯惠科技发展(上海)有限公司 一种人源化抗tpbg抗体及其制备方法、其偶联物和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6245898B1 (en) * 1998-06-15 2001-06-12 The Research Foundation Of State University Of New York Monoclonal antibodies that recognize antigens associated with tumor metastasis
JP2003189851A (ja) * 2001-12-28 2003-07-08 Japan Science & Technology Corp 抗ヒトｃｄ１５１モノクローナル抗体産生ハイブリドーマ
JP2003321494A (ja) * 2002-02-26 2003-11-11 Daiichi Fine Chemical Co Ltd プロｍｍｐ−７の活性化調節方法
WO2007150020A1 (en) * 2006-06-23 2007-12-27 Simon Paul M Targeted immune conjugates
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
FR2929946B1 (fr) * 2008-04-11 2010-05-28 Pf Medicament Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer

Also Published As

Publication number Publication date
HRP20110374T1 (hr) 2011-06-30
US20120219569A1 (en) 2012-08-30
HK1132904A1 (en) 2010-03-12
RU2464041C2 (ru) 2012-10-20
KR20090067219A (ko) 2009-06-24
PL2079482T3 (pl) 2011-07-29
CN101528256A (zh) 2009-09-09
FR2907341A1 (fr) 2008-04-25
RU2009118440A (ru) 2010-11-27
RS51729B (en) 2011-10-31
DE602007012743D1 (de) 2011-04-07
CN101528256B (zh) 2013-10-02
DK2079482T3 (da) 2011-06-14
TN2009000144A1 (fr) 2010-10-18
AU2007310763B2 (en) 2011-02-17
CA2665912A1 (fr) 2008-05-02
AU2007310763A1 (en) 2008-05-02
SI2079482T1 (sl) 2011-07-29
FR2907341B1 (fr) 2012-08-17
ES2361696T3 (es) 2011-06-21
US20090324600A1 (en) 2009-12-31
WO2008049990A2 (fr) 2008-05-02
NZ575781A (en) 2012-06-29
US8178096B2 (en) 2012-05-15
MA30777B1 (fr) 2009-10-01
PT2079482E (pt) 2011-05-25
EP2079482B1 (fr) 2011-02-23
CA2665912C (fr) 2014-12-09
MX2009003039A (es) 2009-04-02
NO20091919L (no) 2009-05-18
IL198043A (en) 2015-03-31
EP2079482A2 (fr) 2009-07-22
JP2013253084A (ja) 2013-12-19
IL198043A0 (en) 2011-08-01
KR101521863B1 (ko) 2015-05-20
WO2008049990A3 (fr) 2008-09-12
JP2010506888A (ja) 2010-03-04
BRPI0717455A2 (pt) 2013-12-24
ATE499387T1 (de) 2011-03-15
JP5757646B2 (ja) 2015-07-29
JP5723420B2 (ja) 2015-05-27

Similar Documents

Publication Publication Date Title
UA99601C2 (ru) Применение антитела к cd151 для лечения первичных опухолей
IL184617A0 (en) Dr5 antibodies and uses thereof
HK1243943A1 (zh) 使用抗IL-1α抗體治療癌症
MX2012004258A (es) Inhibidores de la tirosina quinasa de bruton.
AU2006226897B2 (en) Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors
MX340062B (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y ciclofosfamida.
TW200716646A (en) (S)-N-methylnaltrexone
NZ599875A (en) Human il-23 antigen binding proteins
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
NZ598524A (en) Therapeutic dll4 binding proteins
MY150400A (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
WO2010100056A3 (en) Antibodies against a proliferating inducing ligand (april)
MX2009003362A (es) Uso de interleucina-10 pegilada para tratamiento de cancer.
MX2012008884A (es) Conjugados de anticuerpo y farmaco (adc) que se unen a proteinas 161p2f10b.
MY146112A (en) Long-term feed - cancer patient
WO2010003520A3 (en) Anti-tumor immunotherapy
IN2015DN02349A (ru)
WO2009053038A3 (en) Combination therapy of a type ii anti-cd20 antibody with a proteasome inhibitor
BRPI0514721A (pt) uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
EP2175879A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
PL1869185T3 (pl) Koniugat zawierający białko P21 do leczenia raka
EP2029615B8 (en) A process for the preparation of an oxaliplatin
UA109148C2 (ru) Композиции на основе антитела против vegfr-3